Best GLP-1 Cash-Pay Programs (2026): How PlexusDx Compares to Mochi, Eden, MEDVi, Ro and LillyDirect | PlexusDx

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you're paying out of pocket for a GLP-1, the cash-pay market in 2026 splits into three lanes: brand-name telehealth (GoodRx Care Direct, Ro, Hims & Hers), manufacturer-direct (NovoCare's Wegovy pill and pen, LillyDirect Foundayo and Zepbound), and compounded telehealth (Mochi Health, Eden, MEDVi). Sticker prices range from $129/mo to $499/mo depending on the lane, dose, and whether the platform layers a membership fee on top of medication. PlexusDx Weight Management Protocols sit in the compounded-telehealth lane — Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, and GLP-Squared dual-compound at $249/mo — all-inclusive, no membership, all 50 states, with the optional Precision Peptide Genetic Test as a $99 add-on after month one. This article walks the real cost math across the major cash-pay programs and shows where PlexusDx fits in the lineup.

What “cash-pay” actually means in 2026

A cash-pay GLP-1 program is one designed for patients who are paying out of pocket rather than running medication through commercial insurance. That matters because most U.S. commercial plans still do not cover Wegovy, Zepbound, or other GLP-1s for weight loss as of 2026 — coverage is more common for type 2 diabetes (Ozempic, Mounjaro) than for obesity. Cash-pay platforms compete on three dimensions: the medication source (FDA-approved branded vs compounded), the pricing model (all-inclusive vs membership-plus-medication), and the cancellation terms. PlexusDx is cash-pay, no membership, no commitment, and uses licensed U.S. compounding pharmacies for all six of its Weight Management Protocols. Compounded semaglutide and tirzepatide are not FDA-approved as finished drug products — they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound, prepared under U.S. compounding regulations.

What the major cash-pay programs charge

Here is what each major program advertises as of April 2026, pulled from publicly posted pricing. Mochi Health: $178/mo all-in for compounded semaglutide ($79 membership + $99 medication, flat across all doses), $278/mo for compounded tirzepatide. Eden: compounded semaglutide from $129/mo on the 3-month plan, $229/mo month-to-month, no membership fee. MEDVi: $179 first month, $299/mo refill on compounded semaglutide, no membership. Ro: $149/mo membership plus FDA-approved Wegovy pen at ~$349/mo refill (the Ro membership is separate from the medication cost). GoodRx Care Direct: $39/mo membership plus Wegovy pill at $149/mo first two fills then $299/mo, or Wegovy pen at $199/mo first two fills then $349/mo. NovoCare (manufacturer-direct, no membership): Wegovy pill $149/mo starting dose, Wegovy pen $199/mo first two fills then $349/mo. LillyDirect Foundayo (manufacturer-direct, no membership): orforglipron pill at $149–$299/mo across dose tiers. LillyDirect Zepbound vials: ~$499/mo self-pay. The cheapest entry-level compounded option in this lineup is Eden's 3-month introductory plan at $129/mo and PlexusDx's Microdose GLP-1 Protocol at $129/mo flat — with the difference that PlexusDx's price holds month after month rather than stepping up.

How PlexusDx compares on price and structure

Across the six PlexusDx Weight Management Protocols, the all-in monthly pricing lands at or below the compounded-telehealth competitors at the entry tier and competitive at the higher tiers, with no membership fee at any tier. Microdose GLP-1 Protocol at $129/mo flat is the lowest-cost option for cash-pay patients who want a starter GLP-1 dose in a needle-free format (capsule, troche, lozenge, or sublingual). Semaglutide Injection at $149/mo across five dose levels is meaningfully below MEDVi's $299/mo refill on compounded semaglutide and below Mochi's $178/mo all-in only at the lowest tier. Tirzepatide Injection at $249/mo across six dose levels is below Mochi's $278/mo for compounded tirzepatide at the entry tier and slightly above at the maintenance tier. Semaglutide Oral at $249/mo and Tirzepatide Oral at $279/mo cover the daily-pill format that LillyDirect Foundayo and the Wegovy pill compete in — with the difference that the PlexusDx oral options are compounded rather than FDA-approved branded. The PlexusDx structure is all-inclusive: the monthly price covers the clinician consultation, the prescription, the medication, and shipping in one bill.

The total-cost frame: month one vs annualized

Sticker price at month one is misleading because most programs use introductory pricing that steps up at refill. MEDVi runs $179 month one then $299/mo — roughly $3,468/year on the standard plan. Mochi runs $178/mo all-in — $2,136/year on semaglutide or $3,336/year on tirzepatide. Eden runs $129/mo on the 3-month plan then $229/mo month-to-month — roughly $2,148–$2,748/year depending on plan structure. Ro runs $149/mo membership plus ~$349/mo Wegovy pen — roughly $5,976/year cash-pay. GoodRx Care Direct runs $39/mo plus $149-$289/mo medication — roughly $2,256–$4,656/year. LillyDirect Zepbound vials run ~$499/mo self-pay — ~$5,988/year. PlexusDx annualized pricing: Microdose GLP-1 Protocol $1,548/year, Semaglutide Injection $2,148–$2,748/year, Tirzepatide Injection $2,748–$3,708/year, GLP-Squared $2,148–$3,900/year. Add $99 for the Precision Peptide Genetic Test as a one-time add-on after your first month and the genetic-baseline-included annual total still beats MEDVi at the entry tier and stays competitive across the lineup.

Brand-name vs compounded: what you're actually buying

The medication-source split is the most important non-price decision. NovoCare, LillyDirect, GoodRx Care Direct, and Ro dispense FDA-approved branded GLP-1s — Wegovy (semaglutide injection or pill), Zepbound (tirzepatide injection or vials), Foundayo (orforglipron pill). These products carry full FDA approval, post-market surveillance, and the manufacturer's published label. Mochi Health, Eden, MEDVi, and PlexusDx dispense compounded semaglutide and tirzepatide — pharmacy-prepared formulations of the same active ingredients, prepared by licensed U.S. compounding pharmacies under state and federal compounding regulations. Compounded products are not FDA-approved as finished drugs. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies, regardless of whether the product is branded or compounded. The trade-off is straightforward: branded gives you regulatory clarity at a higher price (when uncovered by insurance); compounded gives you lower cash-pay pricing and broader format options (oral pills, microdose troches, dual-compound stacks) at the cost of FDA-approval status on the finished product.

Why the genetic baseline matters when you're cash-paying

If you're paying out of pocket, you don't want to spend three months titrating up on a medication your biology may respond poorly to. GLP-1 response varies meaningfully across patients — variants in GLP1R, GIPR, FTO, MC4R, and TCF7L2 are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician can anchor titration to a measurable genetic baseline rather than starting from population averages. None of the major cash-pay competitors (Mochi, Eden, MEDVi, Ro, GoodRx, NovoCare, LillyDirect) bundle a pharmacogenomic test with their GLP-1 protocols. PlexusDx offers it standalone for $298 or as a $99 add-on after your first month on any protocol, which makes the genetic-baseline-included total still competitive with MEDVi and Mochi on annualized cost.

Frequently asked questions

What is the cheapest legitimate GLP-1 cash-pay program right now?

For compounded GLP-1, PlexusDx Microdose GLP-1 Protocol at $129/mo flat and Eden's 3-month introductory plan at $129/mo are the lowest verified entry prices, with Mochi Health's $178/mo all-in next. For FDA-approved semaglutide, the Wegovy pill through NovoCare or GoodRx Care Direct at $149/mo (lower doses) is the cheapest starter. For FDA-approved tirzepatide, LillyDirect Zepbound vials at ~$499/mo self-pay is the manufacturer-direct benchmark.

Can I get a GLP-1 without insurance?

Yes. Every major cash-pay program — PlexusDx, Mochi, Eden, MEDVi, Ro, GoodRx Care Direct, NovoCare, and LillyDirect — is designed for patients paying out of pocket. You do need a valid prescription from a licensed clinician. Telehealth platforms (PlexusDx, Mochi, Eden, MEDVi, Ro) include the consultation in the price; manufacturer-direct programs (NovoCare, LillyDirect) require an external prescriber. PlexusDx is available in all 50 states, with five states requiring a scheduled live consultation rather than async intake.

Is brand-name GLP-1 better than compounded GLP-1?

Brand-name GLP-1s (Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro) are FDA-approved as finished drug products, with full clinical trial data and post-market surveillance. Compounded GLP-1s are pharmacy-prepared versions of the same active ingredients and are not FDA-approved as finished products — quality depends on the specific compounding pharmacy. PlexusDx uses licensed U.S. compounding pharmacies. Brand-name carries less regulatory risk; compounded costs less and offers more format options including oral and microdose delivery.

Which GLP-1 cash-pay program has no membership fee?

PlexusDx, Eden, MEDVi, NovoCare, and LillyDirect Foundayo all operate without a separate membership or platform fee — your monthly payment covers medication and (for telehealth options) the consultation. Mochi Health, Ro, GoodRx Care Direct, and Hims & Hers all charge a separate membership on top of medication cost. PlexusDx Weight Management Protocols start at $129/mo flat with no membership.

Which cash-pay program is easiest to cancel?

Manufacturer-direct programs (NovoCare, LillyDirect) are fill-by-fill with no subscription — you simply don't refill. PlexusDx has no membership and no long-term commitment. Among membership-based platforms, Mochi and GoodRx Care Direct have simpler cancellation terms; Ro auto-renews and requires cancellation at least 48 hours before the next billing cycle.

Do GLP-1 cash-pay programs accept HSA or FSA?

GLP-1 medications prescribed by a licensed clinician are generally eligible as HSA/FSA medical expenses, which can reduce your effective cost by 20–35% depending on tax bracket. Many cash-pay programs accept HSA/FSA payment directly — confirm acceptance during enrollment. PlexusDx accepts HSA/FSA cards at checkout for all six Weight Management Protocols.

Why does PlexusDx include a genetic test as an add-on?

GLP-1 response varies across patients based on variants in GLP1R, GIPR, FTO, MC4R, and TCF7L2. The Precision Peptide Genetic Test at $298 standalone or $99 as an add-on after month one anchors dose and titration decisions to a measurable genetic baseline rather than population averages. None of the other major cash-pay programs bundle pharmacogenomics with their GLP-1 protocols, so this is the differentiator on cash-pay value rather than just cash-pay price.

Related reading on PlexusDx

Related reading on PlexusDx: GLP-1 Cost, Cheapest GLP-1, Semaglutide Cost, Tirzepatide Costs.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Pricing for Mochi Health, Eden, MEDVi, Ro, GoodRx Care Direct, NovoCare, and LillyDirect is based on each provider's published rates as of April 2026; actual costs may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision with a licensed clinician.